 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Foundations of Precision Oncology

Introduction to Precision Oncology

Molecular Biomarkers and Testing Strategies

Tyrosine Kinase Inhibitors in Cancer Therapy

Tyrosine Kinase Signaling and Therapeutic Inhibition

EGFR-Targeted Therapy

ALK and ROS1 Fusion-Targeted Therapy

PARP Inhibitors and Homologous Recombination Deficiency

DNA Damage Repair and Homologous Recombination Deficiency

PARP Inhibition and Synthetic Lethality

Immune Checkpoint Blockade in Precision Oncology

Principles of Antitumor Immunity

Biomarkers and Safety Considerations for Checkpoint Blockade

Resistance to Targeted Therapy and Clinical Decision-Making

Mechanisms of Primary and Acquired Resistance

Applying Precision Oncology to Treatment Selection

Quiz

Question 1: Precision Oncology Fundamentals

Question 2: EGFR Tyrosine Kinase Inhibitors

Question 3: ALK and ROS1 Fusions

Question 4: PARP Inhibitors and HRD

Question 5: Treatment Resistance

Survey and Feedback

Course Feedback Survey

Welcome to 'Principles of Precision Oncology and Molecularly Targeted Therapies. ' This comprehensive course is designed to bridge the gap between foundational molecular biology and modern clinical oncology.

Welcome to 'Principles of Precision Oncology and Molecularly Targeted Therapies.' This comprehensive course is designed to bridge the gap between foundational molecular biology and modern clinical oncology. As cancer treatment shifts from traditional, tumor-site-based approaches to highly personalized, biomarker-driven strategies, understanding the underlying mechanisms of targeted therapies is essential for healthcare professionals and researchers. Throughout this course, you will explore the core principles of precision oncology, diving deep into molecular biomarkers, testing strategies like next-generation sequencing (NGS) and liquid biopsies, and the clinical application of targeted treatments. We will cover the critical roles of Tyrosine Kinase Inhibitors (TKIs) in targeting EGFR, ALK, and ROS1 alterations, particularly in non-small cell lung cancer. You will also learn about DNA damage repair, homologous recombination deficiency (HRD), and the concept of synthetic lethality utilizing PARP inhibitors. Furthermore, the course unpacks the revolutionary field of immune checkpoint blockade, examining targets like PD-1, PD-L1, and CTLA-4, alongside the management of immune-related adverse events. Finally, we address the inevitable challenge of treatment resistance, equipping you with the knowledge to navigate primary and acquired resistance mechanisms and make evidence-based clinical decisions. By the end of this course, you will possess a robust understanding of how genomic and proteomic characteristics inform treatment selection, empowering you to contribute to the multidisciplinary care of cancer patients in the era of precision medicine.

Principles of Precision Oncology and Molecularly Targeted Therapies

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>The landscape of cancer treatment has undergone a significant paradigm shift, transitioning from traditional, broad-spectrum, tumor-site-based approaches to highly individualized therapeutic strategies. "Principles of Precision Oncology and Molecularly Targeted Therapies" explores this critical evolution by examining how a tumor's unique genomic, proteomic, and clinical characteristics directly inform treatment selection. The curriculum establishes a rigorous foundation in molecular biomarkers and testing methodologies, detailing the clinical utility of next-generation sequencing, immunohistochemistry, and liquid biopsies. By understanding the fundamental distinctions between predictive and prognostic biomarkers, practitioners are better equipped to interpret actionable alterations, driver mutations, and gene fusions, thereby optimizing multidisciplinary care and patient-specific treatment protocols.</p>

<p>Building upon these foundational diagnostic concepts, the course systematically investigates major classes of targeted treatments and their underlying molecular mechanisms. Detailed modules elucidate the role of tyrosine kinase inhibitors in disrupting abnormal oncogenic signaling pathways, with specific emphasis on EGFR mutations and ALK or ROS1 gene fusions. Furthermore, the curriculum delves into the principles of synthetic lethality utilizing PARP inhibitors in the context of homologous recombination deficiency (HRD), alongside a comprehensive analysis of antitumor immunity and immune checkpoint blockade. Ultimately, the program addresses the complex clinical challenges of primary and acquired therapeutic resistance, providing a stepwise, evidence-based framework for clinical decision-making, the management of targeted and immune-related adverse events, and the equitable application of precision oncology in modern medical practice.</p>
        </div>
    </div>
</div>
